Level Four Advisory Services LLC Raises Stock Holdings in Merit Medical Systems, Inc. (NASDAQ:MMSI)

Level Four Advisory Services LLC lifted its holdings in shares of Merit Medical Systems, Inc. (NASDAQ:MMSI - Free Report) by 17.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,201 shares of the medical instruments supplier's stock after purchasing an additional 2,458 shares during the period. Level Four Advisory Services LLC's holdings in Merit Medical Systems were worth $1,567,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in MMSI. NewSquare Capital LLC purchased a new stake in Merit Medical Systems in the fourth quarter worth $32,000. Kohmann Bosshard Financial Services LLC bought a new position in shares of Merit Medical Systems during the 4th quarter worth $52,000. Smartleaf Asset Management LLC increased its holdings in Merit Medical Systems by 237.7% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,388 shares of the medical instruments supplier's stock worth $134,000 after acquiring an additional 977 shares during the last quarter. GAMMA Investing LLC raised its stake in Merit Medical Systems by 14.7% in the 4th quarter. GAMMA Investing LLC now owns 1,494 shares of the medical instruments supplier's stock valued at $144,000 after acquiring an additional 191 shares during the period. Finally, TD Private Client Wealth LLC lifted its holdings in Merit Medical Systems by 13.9% during the third quarter. TD Private Client Wealth LLC now owns 1,732 shares of the medical instruments supplier's stock valued at $171,000 after purchasing an additional 211 shares during the last quarter. 99.66% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Raymond James lifted their price objective on shares of Merit Medical Systems from $105.00 to $110.00 and gave the company an "outperform" rating in a research note on Tuesday, December 31st. Wells Fargo & Company decreased their price objective on Merit Medical Systems from $120.00 to $117.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Canaccord Genuity Group cut their target price on Merit Medical Systems from $128.00 to $127.00 and set a "buy" rating for the company in a research note on Wednesday, February 26th. Needham & Company LLC reduced their target price on Merit Medical Systems from $122.00 to $116.00 and set a "buy" rating for the company in a report on Wednesday, February 26th. Finally, Barrington Research cut their price objective on shares of Merit Medical Systems from $115.00 to $111.00 and set an "outperform" rating for the company in a research report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Merit Medical Systems currently has a consensus rating of "Moderate Buy" and a consensus price target of $111.70.

Insider Transactions at Merit Medical Systems

In related news, CEO Fred P. Lampropoulos sold 31,320 shares of the firm's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $103.86, for a total transaction of $3,252,895.20. Following the transaction, the chief executive officer now directly owns 1,086,028 shares of the company's stock, valued at approximately $112,794,868.08. This trade represents a 2.80 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Stephen C. Evans sold 5,000 shares of the company's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $105.31, for a total transaction of $526,550.00. Following the completion of the sale, the director now directly owns 4,657 shares of the company's stock, valued at $490,428.67. This trade represents a 51.78 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 109,132 shares of company stock valued at $11,139,521. Insiders own 3.70% of the company's stock.

Merit Medical Systems Price Performance

Merit Medical Systems stock traded down $2.04 during mid-day trading on Thursday, hitting $105.00. 138,322 shares of the company traded hands, compared to its average volume of 452,986. The stock has a fifty day moving average price of $104.42 and a 200-day moving average price of $101.24. The stock has a market cap of $6.18 billion, a price-to-earnings ratio of 51.47, a price-to-earnings-growth ratio of 2.34 and a beta of 0.91. Merit Medical Systems, Inc. has a one year low of $70.70 and a one year high of $111.45. The company has a debt-to-equity ratio of 0.57, a quick ratio of 3.82 and a current ratio of 5.36.

Merit Medical Systems Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.